tempusai

2,279 рет көрілді
8 адам талқылап жатыр
加密王_
·
--
🤖 xTEM: AI IS TRANSFORMING HEALTHCARE! Tempus AI is bringing artificial intelligence and advanced data analytics into modern healthcare. Its focus on precision medicine and clinical intelligence puts it in an exciting technology sector. Healthcare innovation offers significant potential, while competition, regulation, and profitability remain important challenges. Watch $TEM ! #xTEM #tempusai #artificialintelligence #USDTfree
🤖 xTEM: AI IS TRANSFORMING HEALTHCARE!

Tempus AI is bringing artificial intelligence and advanced data analytics into modern healthcare. Its focus on precision medicine and clinical intelligence puts it in an exciting technology sector. Healthcare innovation offers significant potential, while competition, regulation, and profitability remain important challenges. Watch $TEM !

#xTEM #tempusai #artificialintelligence #USDTfree
·
--
Жоғары (өспелі)
$TEM pre-market trades at 78.86 (+10.71%) as Tempus AI reports a strong Q3 earnings beat with $411.5M revenue (+23% YoY) and raises FY26 guidance. Momentum gained further boost from its multi-year strategic collaboration with Moderna and Merck. Daily RSI(6) sits at 70.17 after hitting a 24h high of 83.63. Defending the 75 support could setup another test of 83+ resistance. Are you trading this earnings momentum? ​#TEM #TempusAI #USMidtermElections
$TEM pre-market trades at 78.86 (+10.71%) as Tempus AI reports a strong Q3 earnings beat with $411.5M revenue (+23% YoY) and raises FY26 guidance. Momentum gained further boost from its multi-year strategic collaboration with Moderna and Merck. Daily RSI(6) sits at 70.17 after hitting a 24h high of 83.63. Defending the 75 support could setup another test of 83+ resistance.

Are you trading this earnings momentum?

​#TEM #TempusAI #USMidtermElections
🚨 TEMPEST IN AI HEALTHCARE? $TEM SURGES 36% IN 5 DAYS! Tempus AI ($TEM ) has jumped roughly 36% over five trading sessions, putting AI-powered healthcare back in the spotlight. 🔥 What’s driving the move? • 💰 Management highlighted potential future revenue from Medicare reimbursement changes • 🧬 Up to $80M–$100M potential revenue from its tissue-scanning test • 🩸 Potential $250M–$300M from liquid biopsy if the anticipated approval arrives • 📊 Q2 revenue reached $382.5M, up 22% YoY • 🤖 Tempus continues expanding AI-driven diagnostics, data licensing and precision medicine But after such a sharp move, momentum and valuation risk are worth watching. 👀 The bigger question: Can Tempus turn AI healthcare growth into sustained revenue and profitability? $TEM on your watchlist? Bullish 📈 or waiting for a pullback? 👇 {future}(TEMUSDT) #TempusAI #TEM #AI #Healthcare #StockMarket
🚨 TEMPEST IN AI HEALTHCARE? $TEM SURGES 36% IN 5 DAYS!

Tempus AI ($TEM ) has jumped roughly 36% over five trading sessions, putting AI-powered healthcare back in the spotlight.

🔥 What’s driving the move?

• 💰 Management highlighted potential future revenue from Medicare reimbursement changes
• 🧬 Up to $80M–$100M potential revenue from its tissue-scanning test
• 🩸 Potential $250M–$300M from liquid biopsy if the anticipated approval arrives
• 📊 Q2 revenue reached $382.5M, up 22% YoY
• 🤖 Tempus continues expanding AI-driven diagnostics, data licensing and precision medicine

But after such a sharp move, momentum and valuation risk are worth watching.

👀 The bigger question:
Can Tempus turn AI healthcare growth into sustained revenue and profitability?

$TEM on your watchlist?
Bullish 📈 or waiting for a pullback? 👇
#TempusAI #TEM #AI #Healthcare #StockMarket
Расталды
$RXRX.US Ai生物制药的风,终于吹到了这个小盘股了~ Recursion此前与Tempus AI延长合作至2029年,Tempus还获得RXRX RNA基础模型 TxFM 的全球非独家授权,协议中包含未来三年4200万美元确定性付款。 这意味着RXRX的AI制药平台正在向实际商业化验证推进! 板块大哥$TEM 近期强势异常,已经准备好再次冲击88-90的日线重压区! {future}(TEMUSDT) $MRNA 在9号也就是后天正式进入Nasdaq 100,年内涨幅近600%!目前已回到周线压力208-220,本身利好加上整体板块强势,短线也到了兑现的阶段,不可追涨哦~ {future}(MRNAUSDT) 而RXRX昨天超跌反弹,多军终于发力打击空头!一举拉升到日线压力5-5.2刀附近! 3-3.3买美股彩票的兄弟们又舒服了,彩票狂赚一周早饭!😂 知足常乐~ #Ai生物制药 #tempusai {stock_us}(RXRX.US)
$RXRX.US

Ai生物制药的风,终于吹到了这个小盘股了~

Recursion此前与Tempus AI延长合作至2029年,Tempus还获得RXRX RNA基础模型 TxFM 的全球非独家授权,协议中包含未来三年4200万美元确定性付款。

这意味着RXRX的AI制药平台正在向实际商业化验证推进!

板块大哥$TEM 近期强势异常,已经准备好再次冲击88-90的日线重压区!
$MRNA 在9号也就是后天正式进入Nasdaq 100,年内涨幅近600%!目前已回到周线压力208-220,本身利好加上整体板块强势,短线也到了兑现的阶段,不可追涨哦~

而RXRX昨天超跌反弹,多军终于发力打击空头!一举拉升到日线压力5-5.2刀附近!

3-3.3买美股彩票的兄弟们又舒服了,彩票狂赚一周早饭!😂
知足常乐~

#Ai生物制药 #tempusai
RXRXUS+2,65%
MRNA-4,49%
TEM-0,01%
🤖 xTEM: WHERE ARTIFICIAL INTELLIGENCE MEETS THE FUTURE OF MEDICINE! Artificial intelligence is transforming industries, but one of its most meaningful opportunities could be healthcare. Tempus AI ($TEM ) is developing technology that combines artificial intelligence, clinical data, and advanced diagnostics to support more personalized approaches to medicine. Its business operates at the intersection of healthcare innovation, precision medicine, oncology diagnostics, and data analytics. Tempus delivered impressive Q3 2026 results. Revenue increased 23% year over year to $411.5 million. Its Data and Applications segment grew 33%, while oncology testing volume increased 32%. The company also raised its 2026 revenue guidance to approximately $1.60–$1.605 billion. These developments strengthen the growth narrative, but investors should not ignore the risks. Profitability, competition, healthcare regulations, data privacy, and the costs of expanding AI infrastructure remain important factors. The powerful opportunity: xTEM provides tokenized exposure to a company working to connect healthcare intelligence with artificial intelligence. The next generation of medicine may be increasingly data-driven. Tempus is positioning itself in that transformation, but execution will determine how much long-term value it creates. #xTEM #TempusAI #artificialintelligence: #HealthcareTechnology #USDTfree
🤖 xTEM: WHERE ARTIFICIAL INTELLIGENCE MEETS THE FUTURE OF MEDICINE!

Artificial intelligence is transforming industries, but one of its most meaningful opportunities could be healthcare.

Tempus AI ($TEM ) is developing technology that combines artificial intelligence, clinical data, and advanced diagnostics to support more personalized approaches to medicine.

Its business operates at the intersection of healthcare innovation, precision medicine, oncology diagnostics, and data analytics.

Tempus delivered impressive Q3 2026 results. Revenue increased 23% year over year to $411.5 million. Its Data and Applications segment grew 33%, while oncology testing volume increased 32%.

The company also raised its 2026 revenue guidance to approximately $1.60–$1.605 billion.

These developments strengthen the growth narrative, but investors should not ignore the risks. Profitability, competition, healthcare regulations, data privacy, and the costs of expanding AI infrastructure remain important factors.

The powerful opportunity: xTEM provides tokenized exposure to a company working to connect healthcare intelligence with artificial intelligence.

The next generation of medicine may be increasingly data-driven. Tempus is positioning itself in that transformation, but execution will determine how much long-term value it creates.

#xTEM #TempusAI #artificialintelligence: #HealthcareTechnology #USDTfree
·
--
Жоғары (өспелі)
目前AI能落地现实场景最有用还是医疗+AI, 给病人采集数据,用药记录,诊断,问诊,大数据模型收集,提高医疗效率给人类健康保证 #tempusai
目前AI能落地现实场景最有用还是医疗+AI,
给病人采集数据,用药记录,诊断,问诊,大数据模型收集,提高医疗效率给人类健康保证
#tempusai
Көбірек контент көру үшін кіріңіз
Binance Square платформасында әлемдік криптоқоғамдастыққа қосылыңыз
⚡️ Криптовалюта туралы ең соңғы және пайдалы ақпаратты алыңыз.
💬 Әлемдегі ең ірі криптобиржаның сеніміне ие.
👍 Расталған авторлардың нақты пікірлерін табыңыз.
Электрондық пошта/телефон нөмірі